NextCure, Inc. (NASDAQ:NXTC) Given Average Rating of “Hold” by Brokerages

NextCure, Inc. (NASDAQ:NXTC) has received a consensus recommendation of “Hold” from the five research firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $23.00.

Several analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of NextCure in a report on Monday, April 27th. Zacks Research cut NextCure from a “hold” rating to a “strong sell” rating in a report on Wednesday.

Institutional Trading of NextCure

Institutional investors have recently modified their holdings of the company. Marshall Wace LLP purchased a new stake in shares of NextCure during the 4th quarter worth about $160,000. Millennium Management LLC purchased a new stake in shares of NextCure during the 4th quarter worth about $185,000. Geode Capital Management LLC grew its holdings in shares of NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after purchasing an additional 3,636 shares during the period. Renaissance Technologies LLC grew its holdings in shares of NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after purchasing an additional 5,300 shares during the period. Finally, Boothbay Fund Management LLC purchased a new stake in shares of NextCure during the 4th quarter worth about $988,000. Hedge funds and other institutional investors own 42.65% of the company’s stock.

NextCure Price Performance

NXTC opened at $10.18 on Friday. The stock has a market capitalization of $36.75 million, a price-to-earnings ratio of -0.51 and a beta of 1.43. The business has a 50-day moving average of $11.31 and a two-hundred day moving average of $11.67. NextCure has a 12 month low of $4.44 and a 12 month high of $15.74.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, beating the consensus estimate of ($2.10) by $0.23. Equities research analysts anticipate that NextCure will post -8.98 earnings per share for the current year.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.